A major challenge in post-genomic research is to understand how physiological and pathological phenotypes arise from the networks of expressed genes 1 and to develop powerful tools for translating the information exchanged between gene and the organ system networks.
on the ischaemic mouse hippocampus (Fig.1) . Baicalin (BA), jasminoidin (JA), cholic acid (CA), Concha margaritifera (CM) and nimodipine (NI) 13, 14 have different effects on neurons subjected to an ischaemic insult. IV after occlusion of the middle cerebral artery was significantly smaller after treatment with each compound except CM; the reduction in IV was greatest for NI (Fig.2a, F=17 .01, *P < 0.05, **P < 0.01 vs. vehicle; mean ± SD, ANOVA, n = 7-9). In the vehicle-and sham-treated mice, 24.06% (90/374) of genes differed in their expression in the hippocampus. Although 90 genes exhibited highly significant differences in expression, only one-third (32 genes) of the cDNAs showed average differences greater than twofold ( genes were shared between all groups (Supp Table 1 ) (Fig. 2b) . Based on data from a previous study 15 , these genes were expected to respond to ischaemic injury or are related to hippocampal function, except that Selenbp2 was null. An interesting contradiction is that the eight overlapping genes should contribute most to the pharmacological effect, but this was not supported by direct comparison in PCA (Fig.2c) , which showed that PCA1 accounted for 56.3% and PCA1-2 for 67.8% of the pharmacological variation. This dominant pattern of expression of the top five major genes was clearly associated with G protein-coupled receptors (GPCRs) and Ras transcription, which did not overlap in the larger altered genes that protect against cerebral ischaemia such as RGS6, Cbx3, and Grb2 (Fig.2c ) 16 . Only three overlapping genes in black pane (Fig.2d) contributed to the pharmacological effect based on the changed phenotypes, although 15 genes were shared in all compound groups (Suppl Table 2 ). The PCA showed that another five top genes might contribute to the pharmacological action, of which three genes Rgs6, Cbx3, and Grb2 in black pane were consistent with the above analysis (Fig.2c ). PCA1 accounted for 60.29% and PCA2 14.50% of the variation. We infer that studying the effects of these candidate genes on pharmacological behaviour requires more than direct comparison analysis.
Expressions of the eight selected genes observed by microarray analysis were independently confirmed by Real-time RT-PCR, which showed that Rgs6 had the highest activity (Fig.2e) .
We next designed two two-level factional experiments ( Fig.3a-d Fig.3c) , suggesting the presence of more overlapping genes in the combination treatment ( Fig.3b-d) .
Variations of gene expression profiles of eight pathways (Fig.3e) revealed that the extracellular signal-regulated kinase mitogen-activated protein kinase (Erk-MAPK) network shared different conditions in these treated groups because only some significantly altered genes emerged in this network (Fig.3f) . One challenge that emerged was whether direct comparison analysis of the ROG and NROG could sufficiently reveal essential information about broad changes in so many pathways.
Some differences in gene expression of less than 1.5-fold are robustly associated with behavioural differences 3 and might be as important as those of genes with greater differences in expression condition. The fold change in expression may not be linearly related to phenotype behaviour because a smaller fold change (-1.72) had a higher correlation coefficient (0.95), and a larger fold change (-2.83) had a lower coefficient (0.85) 18 . We hypothesized that GSI could be used to quantitatively analyse the gene expression pattern of mouse hippocampus treated with BA, JA, CA, or NI alone or in combination. The GSI from this approach was greater than the Pearson coefficients, which were all < 0.7, and near to the Euclidean distance (the range not wider than our approach) ( Although usually applied to relatively small numbers of genes 19 , hierarchical clustering in an independent analysis showed that JA+CA with NI, JA+BA with CA, and BA with JA, in three different categories (Fig.4c ).
PCA1-3 accounted for 80% of the variation (Fig.4e) , which was consistent with the clustering among the six groups (Fig.4d) . Both methods validated the results of the GSI determined by varying the combination treatment. In independent experiments, the IV and neurological score was respectively significantly smaller (P = 0.028) in all groups except the CM group than in the vehicle group (Fig.5a,b) . The CIV ( 
Methods Summary

GSI Approach
The similarity between chips can be calculated by pairing comparing gene expression profile. For two gene microarray a and b , containing n genes, the gene expression vector is The similarity between samples from same group can be calculated in the same manner. In addition, it can be used to describe the magnitude of biological variation. Moreover, the similarity of microarray data from different groups can also be calculated according to formula (2) to observe whether they have similar gene expression profile. Here, we used GSI to represent Similarity chip only and data of Similarity block were not shown.
